ELVNHealthcareSmall-Cap
Enliven Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Enliven Therapeutics, Inc. (ELVN), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are ELVN insiders buying or selling?
Enliven Therapeutics, Inc. insiders reported 28 open-market buys ($127.8M) and 195 sells ($178.2M) across 223 Form 4 filings — a net selling position of $50.4M.
Source: SEC EDGAR Form 4
Key Statistics (as of Jul 8, 2026)
Total Form 4 filings
223
SEC EDGAR
Insider filers
25
Insider buys (28)
$127.8M
Insider sells (195)
$178.2M
Insider sentiment
Net sellingNet insider flow of $50.4M in net selling.
Recent ELVN insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 8, 2026 | Lori Anne Kunkel | Director | Sale | 10.0K | $50.49 | $504.9K |
| Jun 24, 2026 | ORBIMED ADVISORS LLC | 10% Owner | Sale | 860.1K | $45.36 | $39.0M |
| Jun 22, 2026 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale | 6.0K | $43.80 | $263.6K |
| Jun 22, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale | 5.0K | $43.80 | $219.0K |
| Jun 17, 2026 | ORBIMED ADVISORS LLC | 10% Owner | Sale | 281.4K | $45.02 | $12.7M |
| Jun 9, 2026 | Lori Anne Kunkel | Director | Sale | 10.0K | $34.54 | $345.4K |
| May 20, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale | 5.0K | $39.79 | $199.0K |
| Apr 22, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale | 5.0K | $47.67 | $238.4K |
| Mar 27, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale | 40.0K | $35.10 | $1.4M |
| Mar 19, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale | 5.0K | $27.76 | $138.8K |
| Mar 11, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale | 40.0K | $30.07 | $1.2M |
| Mar 10, 2026 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale | 10.0K | $29.58 | $295.8K |
| Feb 19, 2026 | Richard A. Heyman | Director | Sale | 1.2K | $26.18 | $32.2K |
| Feb 19, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale | 45.0K | $26.17 | $1.2M |
| Feb 10, 2026 | Joseph P Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale | 5.0K | $29.04 | $145.2K |
| Jan 22, 2026 | Joseph P Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale | 20.0K | $26.75 | $535.1K |
| Jan 22, 2026 | Richard A. Heyman | Director | Sale | 1.2K | $26.75 | $32.9K |
| Jan 13, 2026 | Anish Patel | CHIEF OPERATING OFFICER | Sale | 48.3K | $27.99 | $1.4M |
| Jan 12, 2026 | Joseph P Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale | 132.5K | $26.23 | $3.5M |
| Jan 12, 2026 | Richard A. Heyman | Director | Sale | 13.9K | $25.02 | $348.3K |
| Dec 23, 2025 | Joseph P Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale | 5.0K | $16.84 | $84.2K |
| Dec 10, 2025 | Anish Patel | CHIEF OPERATING OFFICER | Sale | 6.7K | $21.02 | $140.1K |
| Nov 21, 2025 | Joseph P Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale | 12.5K | $22.33 | $279.2K |
| Nov 19, 2025 | Samuel Kintz | PRESIDENT AND CEO | Sale | 12.5K | $21.82 | $272.7K |
| Nov 12, 2025 | Anish Patel | CHIEF OPERATING OFFICER | Sale | 6.7K | $17.40 | $116.0K |
Showing the 25 most recent of 223 Form 4 filings for Enliven Therapeutics, Inc..
Most active ELVN insiders
- Benjamin Hohl37 filings
- Joseph P Lyssikatos36 filings
- Samuel Kintz32 filings
- Anish Patel26 filings
- Richard A. Heyman19 filings
Ask anything about ELVN insider activity
Use Trabud's AI agent to query Enliven Therapeutics, Inc.'s Form 4 history in plain English — "Show me ELVN CEO purchases this year" or compare it against any other ticker.
Open the AI agentELVN insider trading FAQ
Are Enliven Therapeutics, Inc. insiders buying or selling?
Across 223 SEC Form 4 filings, Enliven Therapeutics, Inc. (ELVN) insiders reported 28 open-market purchases totaling $127.8M and 195 sales totaling $178.2M. That is a net selling position of $50.4M.
How many insiders trade ELVN stock?
25 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Enliven Therapeutics, Inc.. The most recent filing was accepted on Jul 8, 2026.
Where does Trabud get ELVN insider trading data?
All ELVN insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.